Eversept Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Eversept Partners’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-103,829	Closed	-$1.31M	–	101
2020 Q4	$1.31M	Hold	103,829	–	–	0.15%	48
2020 Q3	$1.02M	Sell	103,829 -129,154	-55%	-$1.27M	0.23%	41
2020 Q2	$2.32M	Buy	+232,983	New	+$2.23M	0.32%	45
2019 Q2	–	Sell	-47,154	Closed	-$569K	–	70
2019 Q1	$569K	Buy	+47,154	New	+$695K	0.17%	45

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners's CNCE Position: Q1 2021 in Review

Eversept Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 103,829 shares — an estimated $1.31M sold.

Eversept Partners first reported a position in CNCE in Q1 2019 and held it in 4 quarters. The position peaked at $2.32M in Q2 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

Eversept Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Eversept Partners sold 103,829 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $1.31M.
Eversept Partners first reported a position in Concert Pharmaceuticals, Inc. in Q1 2019 and held it in 4 quarters.
Eversept Partners's Concert Pharmaceuticals, Inc. position peaked at $2.32M in Q2 2020.
91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.